Posted by Michael Wonder on 06 Jun 2023
Fennec Pharmaceuticals announces European Commission marketing authorisation for Pedmarqsi (sodium thiosulphate) to reduce the risk of hearing loss in paediatric oncology patients
6 June 2023 - Pedmarqsi is the first and only approved therapy in the European Union for reducing the risk of cisplatin-induced hearing loss (ototoxicity) in paediatric patients with localised, non-metastatic solid tumours.
Fennec Pharmaceuticals today announced Pedmarqsi– known as Pedmark in the US – was granted marketing authorisation by the European Commission.
